DR info

臨床試験数 : 275 / 薬物数 : 258 - (DrugBank : 82) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 140

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

000000000
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
A-623 or AMG 623
   Anthera Pharmaceuticals, Inc
      2014   Phase 2;Phase 3   EUCTR2014-001365-26-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom;
   Anthera pharmaceuticals, Inc
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;
      2015   -   EUCTR2014-001365-26-SE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;
      2015   -   EUCTR2014-001365-26-IT   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;
      2015   -   EUCTR2014-001365-26-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;
A07EA06
   CROWN OY
      2012   -   EUCTR2012-001923-11-IT   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
ACE Inhibitor or Angiotensin receptor antagonist
   Peking University First Hospital
      2016   -   NCT03015974   China;
ACE inhibitor
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of;
ACE/ARB
   Mayo Clinic
      2009   Phase 4   NCT00498368   United States;
ACEI/ARB and corticosteroids
   Chulalongkorn University
      2012   Phase 4   NCT02571842   Thailand;
ACEi
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States;
ACTH (Acthar) Gel
   Mayo Clinic
      2015   Phase 3   NCT02282930   United States;
ACTHIB - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONCINO POLVERE+1 SIRINGA PRERIEMPITA SOLVENTE 0.5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
ALN-CC5
   Alnylam Pharmaceuticals Inc
      2019   Phase 2   EUCTR2018-002716-27-SE   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002716-27-GB   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-002716-27-ES   Australia;Canada;France;Germany;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
ALXN1210
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2020-001537-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-001537-13-SE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001537-13-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001537-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
APL-2
   Apellis Pharmaceuticals, Inc.
      2018   Phase 2   NCT03453619   United States;
ARB
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of;
ARO-C3
   Arrowhead Pharmaceuticals
      2022   Phase 1   NCT05083364   New Zealand;
AT-1501
   Eledon Pharmaceuticals
      2022   Phase 2   NCT05125068   -
ATG-F
   Centre Hospitalier Universitaire de Saint Etienne
      2011   Phase 4   NCT02523768   France;
AVB-S6-500
   Aravive, Inc.
      2019   Phase 2   NCT04042623   United States;
Abelmoschus manihot
   Chen Xiangmei
      2014   Phase 4   NCT02231125   China;
Acthar 80 unit injection
   Baylor College of Medicine
      2015   Phase 4   NCT02382523   United States;
Aliskiren
   Chinese University of Hong Kong
      2009   Phase 3   NCT00870493   Hong Kong;
   Columbia University
      2009   Phase 4   NCT01129557   United States;
   Kagawa University
      2010   Phase 4   NCT01184599   Japan;
   The University of Hong Kong
      2009   Phase 4   NCT00922311   China;
Allopurinol
   Sun Yat-sen University
      2007   -   NCT00793585   China;
Angiotensin II
   Japanese Study Group of Multiple drug therapy for IgAN
      2004   -   JPRN-C000000341   Japan;
Angiotensin blockade
   The University of Hong Kong
      2002   Phase 4   NCT00863252   China;
Artesunate
   Dongzhimen Hospital, The First Affiliated Hospital of Beijing University of Chinese Medicine
      2020   Phase 0   ChiCTR2000038104   China;
Atacicept
   EMD Serono Research & Development Institute, Inc.
      2017   Phase 2   NCT02808429   Germany;Japan;United Kingdom;United States;
   Merck Biopharma Co., Ltd.
      2017   Phase 2   JPRN-JapicCTI-183956   Japan, Europe;
   Vera Therapeutics, Inc.
      2021   Phase 2   NCT04716231   Australia;Belgium;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Turkey;United Kingdom;United States;
Atrasentan
   CHINOOK THERAPEUTICS, U.S., Inc
      2021   Phase 3   EUCTR2020-003084-26-IT   Argentina;Australia;Brazil;Canada;China;France;Germany;Hong Kong;India;Italy;Japan;Korea, Republic of;New Zealand;Poland;Spain;Taiwan;United Kingdom;United States;
   Chinook Therapeutics U.S., Inc.
      2021   Phase 2   NCT04573920   Australia;Italy;Korea, Republic of;Spain;United Kingdom;United States;
      2020   Phase 3   NCT04573478   Australia;Brazil;Canada;France;Germany;Hong Kong;Italy;Japan;Korea, Republic of;New Zealand;Poland;Spain;Taiwan;United States;
   Yamada Shuji
      2021   Phase 3   JPRN-jRCT2071210028   Argentina;Australia;Brazil;Canada;China;Colombia;Czech Republic;France;Germany;Hong Kong;India;Italy;Japan;New Zealand;Poland;South Korea;Spain;Taiwan;United Kingdom;United States;
Azathioprine
   A. Manzoni Hospital
      1999   Phase 3   NCT01392833   -
BCX9930 hydrochloride
   BIOCRYST PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-005855-19-IT   France;Germany;Italy;Spain;United Kingdom;
   BioCryst Pharmaceuticals Inc
      2021   Phase 2   EUCTR2020-005855-19-ES   France;Germany;Italy;Spain;United Kingdom;
BENLYSTA® (belimumab)
   University of Leicester
      2019   Phase 2   EUCTR2017-004366-10-GB   United Kingdom;
BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
BION-1301 Multiple Doses
   Chinook Therapeutics, Inc.
      2019   Phase 1/Phase 2   NCT03945318   United Kingdom;United States;
BION-1301 Single Dose
   Chinook Therapeutics, Inc.
      2019   Phase 1/Phase 2   NCT03945318   United Kingdom;United States;
BNJ441
   Alexion Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-001537-13-SE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001537-13-ES   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001537-13-DE   Australia;Belgium;Canada;France;Germany;Italy;Korea, Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Bardoxolone methyl capsules
   Reata Pharmaceuticals, Inc.
      2017   Phase 2   NCT03366337   United States;
Blisibimod
   Anthera Pharmaceuticals
      2014   Phase 3   NCT02052219   -
      2013   Phase 2/Phase 3   NCT02062684   Canada;Czech Republic;Czechia;Germany;Hong Kong;Italy;Korea, Republic of;Malaysia;Philippines;Russian Federation;Singapore;Spain;Taiwan;Thailand;United Kingdom;
Blisibimod Injection
   Anthera Pharmaceuticals, Inc
      2014   Phase 2;Phase 3   EUCTR2014-001365-26-CZ   Canada;Czech Republic;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;United Kingdom;
   Anthera pharmaceuticals, Inc
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-ES   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;
      2015   Phase 2;Phase 3   EUCTR2014-001365-26-DE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;
      2015   -   EUCTR2014-001365-26-SE   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Malaysia;Philippines;Poland;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Ukraine;United Kingdom;
      2015   -   EUCTR2014-001365-26-IT   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;
      2015   -   EUCTR2014-001365-26-HU   Argentina;Belarus;Belgium;Brazil;Bulgaria;Canada;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Netherlands;Philippines;Poland;Portugal;Romania;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;
Blood sample
   Centre Hospitalier Universitaire de Saint Etienne
      2012   -   NCT02526966   France;
Bortezomib (Velcade®)
   The Rogosin Institute
      2010   Phase 4   NCT01103778   United States;
Budesonide
   Pharmalink AB
      2005   Phase 2   NCT00767221   Sweden;
C09
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
CCX168
   ChemoCentryx, Inc.
      2015   Phase 2   EUCTR2014-003402-33-SE   Belgium;Sweden;United States;
      2015   Phase 2   EUCTR2014-003402-33-BE   Belgium;Sweden;United States;
Calcitriol
   Chinese University of Hong Kong
      2006   Phase 4   NCT00319761   Hong Kong;
   Osaka University HospitalDepartment of nephrology
      2007   -   JPRN-UMIN000002474   Japan;
   Yonsei University
      2011   -   NCT01237028   Korea, Republic of;
Cemdisiran
   Alnylam Pharmaceuticals
      2019   Phase 2   NCT03841448   Canada;France;Malaysia;Philippines;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Chinese Herb Prescription Granule plus prednisone
   Shanghai University of Traditional Chinese Medicine
      2010   -   NCT01879514   China;
Cilazapril
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China;
Corticosteroid
   Peking University First Hospital
      2016   -   NCT03015974   China;
   Yonsei University
      2016   Phase 4   NCT02981212   Korea, Republic of;
Corticotherapy
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03188887   France;
Cyclophosphamid
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany;
Cyclophosphamide
   Peking University First Hospital
      2016   -   NCT03015974   China;
Decortin H
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany;
Dihuang
   Zhejiang Provincal Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042331   China;
Dipyridamole
   Peking University First Hospital
      2016   -   NCT03015974   China;
      2013   -   ChiCTR-TRC-13003038   China;
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan;
   The Japanese Pediatric IgA Nephropathy ofTreatment Study Group
      2001   -   JPRN-C000000363   Japan;
      1998   -   JPRN-C000000374   Japan;
ENALAPRIL VALSARTAN METHYLPREDNISONE
   Hospital Britanico
      1996   Phase 4   NCT00367562   Argentina;
Enalapril
   ARB therapeutic society of IgA nephropathy
      2003   Phase 4   JPRN-C000000380   Japan;
   National Center for Research Resources (NCRR)
      2000   -   NCT00006137   -
FOS
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States;
FOSTAMATINIB DISODIUM
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Fecal microbiota transplantation
   Air Force Military Medical University, China
      2017   Phase 2   NCT03633864   China;
Felzartamab
   MorphoSys AG
      2021   Phase 2   NCT05065970   Australia;Belgium;Bulgaria;Germany;Korea, Republic of;Malaysia;Serbia;Spain;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-ES   Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Fostamatinib
   Rigel Pharmaceuticals
      2014   Phase 2   NCT02112838   Austria;Germany;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Fostamatinib 100 mg tablet
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Fostamatinib 150 mg tablet
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
Fostamatinib Disodium tablet
   Rigel Pharmaceuticals
      2015   Phase 2   NCT02433236   -
GSK1550188
   University of Leicester
      2019   Phase 2   EUCTR2017-004366-10-GB   United Kingdom;
Gastrus
   Uppsala University Hospital
      2013   -   NCT01781312   Sweden;
HAEMOPHILUS INFLUENZAE
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
HIBERIX - POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO INTRAMUSCOLARE 1 FLACONCINO DI POLVERE + 1 SIRINGA PRERIEMPITA DI SOLVENTE DA 0.5 ML
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
HR19042 Capsules
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 2   NCT05016323   China;
HR19042 capsule
   Jiangsu HengRui Medicine Co., Ltd.
      2021   Phase 1   NCT04887532   China;
High Dose-VIS649
   Visterra, Inc.
      2020   Phase 2   NCT04287985   Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States;
Hormone (prednisone)
   Shanghai University of Traditional Chinese Medicine
      2016   -   NCT02712697   China;
Human soluble recombinant Fc-gamma receptor IIB
   Baxalta Innovations GmbH
      2015   -   EUCTR2015-002345-64-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States;
Hydroxychloroquine
   Department of Pharmacy, Drum Tower Hospital Affiliated to Nanjing University Medical School
      2021   Phase 1   ChiCTR2100052910   China;
   Peking University First Hospital
      2021   Phase 0   ChiCTR2100045306   China;
Hydroxychloroquine Sulfate
   LLiu
      2015   Phase 4   NCT02351752   China;
   Peking Union Medical College Hospital
      2016   Phase 4   NCT02765594   China;
   Peking University First Hospital
      2016   Phase 2   NCT02942381   China;
IONIS-FB-LRx
   Ionis Pharmaceuticals, Inc.
      2019   Phase 2   NCT04014335   Australia;Canada;New Zealand;
Immunosuppressants
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT03418779   China;
Immunosuppressive treatment
   Yonsei University
      2019   Phase 4   NCT03468972   Korea, Republic of;
Infusion of ADR-001 (Mesenchymal stem cell)
   Nagoya University
      2020   Phase 1   NCT04342325   Japan;
Intervention for incipient patients at low risk of disease progression
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2020   -   NCT04438603   China;
Intervention for patients at high risk of disease progression
   Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
      2020   -   NCT04438603   China;
Intravenous Rituximab
   Chulalongkorn University
      2012   Phase 4   NCT02571842   Thailand;
   Mayo Clinic
      2009   Phase 4   NCT00498368   United States;
Iptacopan
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-002200-40-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-002200-40-NO   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-002200-40-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-002200-40-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2021   Phase 3   EUCTR2020-001049-38-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2021   Phase 3   EUCTR2020-001049-38-NO   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2020   Phase 3   EUCTR2020-001049-38-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2020   Phase 3   EUCTR2020-001049-38-FI   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2020   Phase 3   EUCTR2020-001049-38-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2019   Phase 2   EUCTR2017-000891-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-FI   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000891-27-GB   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Irbesartan
   AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
      2005   -   EUCTR2005-003885-40-IT   Italy;
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China;
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03762850   Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Irbesartan tablets (ANDA 203071)
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-GB   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States;
Irbesartan tablets (NDA 020 757)
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
LNP023
   Novartis Pharmaceuticals
      2021   Phase 3   NCT04578834   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   NCT04557462   Belgium;Germany;
      2018   Phase 2   NCT03373461   Argentina;Australia;Belgium;Brazil;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Netherlands;Norway;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
Leflunomide
   Chinese General Hospital of PLA
      2010   -   ChiCTR-TRC-10000776   China;
   The First Affiliated Hospital of Chengdu Medical College
      2018   -   ChiCTR1800019606   China;
Leflunomide 20 mg+prednisone 0.5mg/kg/d
   Shenzhen Second People's Hospital
      2019   Phase 4   NCT04020328   China;
Lisinopril
   Japanese Study group of Kidney Disease in Children
      2005   -   JPRN-C000000006   Japan;
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000373   Japan;
Losartan
   Chen Xiangmei
      2014   Phase 4   NCT02231125   China;
   Fan Fan Hou
      2013   -   NCT01854814   China;
   Fukuoka University Faculty of Medicine
      2009   -   JPRN-UMIN000002887   Japan;
   Japanese Study group of Kidney Disease in Children
      2005   -   JPRN-C000000006   Japan;
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China;
   The Third Xiangya Hospital of Central South University
      2018   Phase 4 study   ChiCTR-IIR-17013487   China;
Low Dose-VIS649
   Visterra, Inc.
      2020   Phase 2   NCT04287985   Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States;
Low antigen content diet
   Uppsala University Hospital
      2010   -   NCT01203007   Norway;Sweden;
MASP-2 Antibody, OMS00620646, OMS620646
   Omeros Corporation
      2019   Phase 3   EUCTR2018-000075-33-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-SK   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-LT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-BG   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
MENVEO - POLV.E SOLUZ.PER SOLUZ. INIETT.-USO INTRAMUSCOLARE-COMP. CONIUG.LIOFILIZZ.MENA:FLAC.(VETRO) COMP. GONIUG.LIQUI.MENCWY:FLAC.(VETRO)-1 FLAC+1FLAC
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
METHYLPREDNISOLONE MYLAN Générique
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2016-004507-31-FR   France;
MMF
   Zhongshan Hospital of Fudan University
      2008   -   ChiCTR-TRC-09000607   China;
MOR03087
   MorphoSys AG
      2021   Phase 2   EUCTR2020-005054-19-ES   Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
MOR202
   MorphoSys AG
      2021   Phase 2   EUCTR2020-005054-19-ES   Australia;Belgium;Bulgaria;Canada;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-DE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-CZ   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-BG   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-005054-19-BE   Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Georgia;Germany;Japan;Korea, Republic of;Malaysia;Philippines;Serbia;Spain;Taiwan;Ukraine;United Kingdom;United States;
Medium Dose-VIS649
   Visterra, Inc.
      2020   Phase 2   NCT04287985   Australia;Canada;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Sri Lanka;Taiwan;Thailand;United Kingdom;United States;
Menatetrenone
   Osaka University HospitalDepartment of nephrology
      2007   -   JPRN-UMIN000002474   Japan;
Methylprednisolon
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany;
Methylprednisolone
   A. Manzoni Hospital
      1999   Phase 3   NCT01392833   -
   Sixth Affiliated Hospital, Sun Yat-sen University
      2021   Phase 3   NCT04833374   China;
   The George Institute
      2012   -   NCT01560052   Australia;Canada;China;Hong Kong;India;Malaysia;
   West Japan Study Group for Therapy of IgA Nephropathy
      2006   -   JPRN-UMIN000000593   Japan;
   Zhongshan Hospital of Fudan University
      2008   -   ChiCTR-TRC-09000607   China;
Methylprednisolone (MP) or prednisone (pred)
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China;
Methylprednisolone pulse
   Peking University First Hospital
      2016   Phase 2/Phase 3   NCT02647255   China;
Methylprednisolone(intravenously in the 1st-2nd-3rd month )
   Sun Yat-sen University
      2014   Phase 2   NCT02160132   China;
Methylprednisolone(intravenously in the 1st-3rd-5th month)
   Sun Yat-sen University
      2014   Phase 2   NCT02160132   China;
Mezagitamab
   Takeda
      2022   Phase 1   NCT05174221   -
Mizoribine
   Japanese Study Group of Multiple drug therapy for IgAN
      2004   -   JPRN-C000000341   Japan;
   Nanjing general hospital of Nanjing military command
      2011   -   ChiCTR-ONC-10001124   China;
   Peking University First Hospital
      2013   -   ChiCTR-TRC-13003038   China;
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan;
   The Japanese Pediatric IgA Nephropathy ofTreatment Study Group
      2001   -   JPRN-C000000363   Japan;
   West Japan Study Group for Therapy of IgA Nephropathy
      2006   -   JPRN-UMIN000000593   Japan;
Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)
   Second Xiangya Hospital of Central South University
      2014   Phase 3   NCT02187900   China;
Mycophenolat-Natrium
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany;
Mycophenolate Mofetil (MMF)
   St. Joseph's Hospital and Medical Center, Phoenix
      2002   Phase 3   NCT00318474   United States;
Mycophenolate mofetil
   Fan Fan Hou
      2013   -   NCT01854814   China;
   Nanjing University School of Medicine
      2003   -   NCT00301600   China;
   Peking University First Hospital
      2016   -   NCT03015974   China;
   The University of Hong Kong
      2002   Phase 4   NCT00863252   China;
Mycophenolate mofetil (MMF)
   Second Xiangya Hospital of Central South University
      2014   Phase 3   NCT02187900   China;
   Sun Yat-sen University
      2007   Phase 3   NCT00657059   China;
Mycophenolate mofetil plus lower dose of Prednisone
   Zhi-Hong Liu, M.D.
      2010   -   NCT01269021   China;
Mycophenolate sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Mycophenolic acid
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Mycophenolic sodium
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Myfortic
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany;
Myfortic 180mg Tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
Myfortic 360mg Tablets
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
NEFECON
   Pharmalink AB
      2012   Phase 2   NCT01738035   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Narsoplimab
   Omeros Corporation
      2019   Phase 3   EUCTR2018-000075-33-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-SK   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-LT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-BG   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
Nefecon
   CALLIDITAS THERAPEUTICS AB
      2020   Phase 3   EUCTR2020-003308-14-IT   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-IT   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;
   CROWN OY
      2012   -   EUCTR2012-001923-11-IT   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
   Calliditas Therapeutics AB
      2021   Phase 3   EUCTR2020-003308-14-FI   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   NCT04541043   Sweden;
      2020   Phase 3   EUCTR2020-003308-14-SE   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003308-14-PL   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003308-14-GR   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003308-14-GB   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003308-14-FR   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2020   Phase 3   EUCTR2020-003308-14-CZ   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   NCT03643965   Argentina;Australia;Belarus;Belgium;Canada;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-SE   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-PL   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-GB   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-FI   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-ES   Argentina;Australia;Belarus;Belgium;Canada;Czech Republic;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-CZ   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004902-16-BE   Argentina;Australia;Belarus;Belgium;Canada;China;Czech Republic;Czechia;Finland;France;Germany;Greece;Italy;Korea, Republic of;Poland;Spain;Sweden;Taiwan;Turkey;United Kingdom;United States;
   Pharmalink AB
      2013   -   EUCTR2012-001923-11-ES   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2012-001923-11-DK   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2012-001923-11-DE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2012-001923-11-CZ   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2012-001923-11-BE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-001923-11-SE   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-001923-11-NL   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-001923-11-GB   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2012-001923-11-FI   Belgium;Czech Republic;Denmark;Finland;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
OMS721
   OMEROS CORPORATION
      2019   Phase 3   EUCTR2018-000075-33-IT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United Kingdom;United States;
   Omeros Corporation
      2021   Phase 3   EUCTR2018-000075-33-GR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Czechia;Germany;Greece;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000075-33-GB   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2019   Phase 3   EUCTR2018-000075-33-DE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   NCT03608033   Australia;Austria;Belgium;Bulgaria;Hungary;Lithuania;Poland;Slovakia;Spain;United States;
      2018   Phase 3   EUCTR2018-000075-33-SK   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-SE   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;China;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-PL   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-LT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-HU   Australia;Canada;Hungary;United States;
      2018   Phase 3   EUCTR2018-000075-33-ES   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;France;Germany;Hungary;Italy;Lithuania;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-CZ   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-BG   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-BE   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Lithuania;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 3   EUCTR2018-000075-33-AT   Australia;Austria;Belgium;Bulgaria;Canada;Czech Republic;Hungary;Korea, Republic of;Lithuania;Malaysia;Philippines;Poland;Singapore;Slovakia;Spain;Sweden;Taiwan;United States;
OMS721 (narsoplimab)
   Omeros Corporation
      2016   Phase 2   NCT02682407   Hong Kong;United States;
OPL-CCL2-LPM
   Osprey Pharmaceuticals USA, Inc.
      2009   Phase 1   NCT00856674   Canada;
Omega-3 Fatty Acid Fish Oil Supplement
   Mayo Clinic
      2009   Phase 4   NCT00498368   United States;
Omega-3 fatty acid ethylester90
   Kuhnil Pharmaceutical Co., Ltd.
      2007   Phase 3   NCT00549692   Korea, Republic of;
Over-encapsulated 150 mg Irbesartan Tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States;
Over-encapsulated Irbesartan Tablets
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-HR   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004605-41-PL   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-LT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-EE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-CZ   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-BE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
PNEUMOVAX – Soluzione iniettabile in siringa preriempita da 0,5 ml
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
PREDNISONE ARROW
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2017   Phase 3   EUCTR2016-004507-31-FR   France;
Paricalcitol
   Chinese University of Hong Kong
      2008   Phase 3   NCT00599963   China;Hong Kong;
Placebo
   Merck Biopharma Co., Ltd.
      2017   Phase 2   JPRN-JapicCTI-183956   Japan, Europe;
Plasma Exchange (PE)
   Peking University First Hospital
      2016   Phase 2/Phase 3   NCT02647255   China;
Potassium
   The Third Xiangya Hospital of Central South University
      2018   Phase 4 study   ChiCTR-IIR-17013487   China;
Prednisolon
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany;
   Universitätsklinikum Ulm
      2008   -   EUCTR2007-000443-99-DE   Germany;
Prednisolone
   Japanese Study Group of Multiple drug therapy for IgAN
      2004   -   JPRN-C000000341   Japan;
   Juntendo University
      2018   -   JPRN-UMIN000032031   Japan;
   Nephrology Department, Hangzhou Hospital of Traditional Chinese Medicine, Zhejiang Province
      2019   Phase 0   ChiCTR1900026883   China;
   Sun Yat-sen University
      2016   Phase 2/Phase 3   NCT02662283   China;
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan;
   The Japanese Pediatric IgA Nephropathy ofTreatment Study Group
      2001   -   JPRN-C000000363   Japan;
      1998   -   JPRN-C000000374   Japan;
   UHB NHS Foundation Trust
      2010   Phase 2   EUCTR2009-016003-26-GB   United Kingdom;
   West Japan Study Group for Therapy of IgA Nephropathy
      2006   -   JPRN-UMIN000000593   Japan;
Prednisone
   A. Manzoni Hospital
      1999   Phase 3   NCT01392833   -
   Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine
      2010   -   ChiCTR-TRC-13003702   China;
   The First Affiliated Hospital of Xi'an Jiaotong University Medical College
      2010   -   ChiCTR-TRC-10000824   China;
   The First Affiliated Hospital of Zhejiang University
      2009   -   ChiCTR-TRC-09000338   China;
   The First Hospital, Peking University
      2006   -   ChiCTR-TRC-06000004   China;
   Yancheng Third People's Hospital
      2011   -   ChiCTR-OPN-16010028   -
Prednisone + Inhibace/Cozaar
   Peking University
      2006   -   NCT00378443   -
Prednisone alone
   Guangdong General Hospital
      2016   Phase 4   NCT03218852   China;
      2012   Phase 4   NCT01758120   China;
Prednisone and cyclophosphamide
   Guangdong General Hospital
      2016   Phase 4   NCT03218852   China;
Prednisone in full dose
   Zhi-Hong Liu, M.D.
      2010   -   NCT01269021   China;
Prednisone or Prednisolone
   Nanjing University School of Medicine
      2011   -   NCT01451710   China;
Prednisone plus cyclophosphamide
   Guangdong General Hospital
      2012   Phase 4   NCT01758120   China;
ProTectis
   Uppsala University Hospital
      2013   -   NCT01781312   Sweden;
Probucol
   Guangdong General Hospital
      2007   Phase 4   NCT00426348   China;
R935788
   Rigel Pharmaceuticals Inc
      2014   Phase 2   EUCTR2014-000331-16-GB   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
      2014   Phase 2   EUCTR2014-000331-16-AT   Austria;Hong Kong;Singapore;Switzerland;Taiwan;United Kingdom;United States;
RAS 2410
   CHENNAN
      2020   Phase 4   NCT04525729   China;
RC18
   RemeGen Co., Ltd.
      2020   Phase 2   NCT04291781   China;
RE-021
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-HR   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-GB   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-ES   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Hungary;Italy;Korea, Republic of;Lithuania;Malaysia;New Zealand;Poland;Portugal;Spain;Turkey;United Kingdom;United States;
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004605-41-PL   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-LT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-EE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-CZ   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-BE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2021   Phase 2   EUCTR2021-000621-27-ES   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-PL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-NL   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2021-000621-27-DE   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   University of Leicester
      2019   Phase 2   EUCTR2018-002012-27-GB   United Kingdom;
Ramipril
   AZIENDA OSPEDALIERA PROVINCIALE DI LECCO
      2005   -   EUCTR2005-003885-40-IT   Italy;
   Chinese University of Hong Kong
      2002   Phase 3   NCT01225445   Hong Kong;
   The Chinese University of Hong Kong
      2004   -   ChiCTR-TRC-09000630   China;
Ravulizumab
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2020-001537-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
Reh-acteoside
   Sun Yat-sen University
      2016   Phase 2/Phase 3   NCT02662283   China;
Renin Angiotensin system (RAS) blockade
   Assistance Publique - Hôpitaux de Paris
      2018   Phase 3   NCT03188887   France;
Risedronate
   Osaka University HospitalDepartment of nephrology
      2007   -   JPRN-UMIN000002474   Japan;
Rituximab
   CHENNAN
      2020   Phase 4   NCT04525729   China;
   Ruijin Hospital, Shanghai Jiaotong University School of Medicine
      2020   Phase 4   ChiCTR2000036468   China;
SM101
   Baxalta Innovations GmbH
      2015   -   EUCTR2015-002345-64-CZ   Belgium;Canada;Czech Republic;Denmark;Germany;Hong Kong;Sweden;United Kingdom;United States;
   Baxalta now part of Shire
      2015   Phase 2   NCT02605525   -
SMOFKABIVEN - EMULSIONE PER INFUSIONE SENZA ELETTROLITI 1 SACCA BIOFINE MULTICOMPARTIMENTATE DA 493 ML
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Simulect
   Centre Hospitalier Universitaire de Saint Etienne
      2011   Phase 4   NCT02523768   France;
Simvastatin
   Fukuoka University Faculty of Medicine
      2009   -   JPRN-UMIN000002887   Japan;
Sirolimus (study drug)+ACE inhibitor + statin
   Josep m Cruzado
      2006   Phase 2   NCT00396721   Spain;
Sparsentan
   TRAVERE THERAPEUTICS, INC
      2022   Phase 2   EUCTR2021-000621-27-IT   France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States;
   Travere Therapeutics, Inc.
      2018   Phase 3   NCT03762850   Australia;Belgium;Croatia;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Sparsentan compresse
   RETROPHIN, INC
      2018   Phase 3   EUCTR2017-004605-41-IT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Sparsentan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-HR   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Sparsentan tablets/ Over-encapsulated Sparsentan tablets
   Travere Therapeutics Inc.
      2018   Phase 3   EUCTR2017-004605-41-BE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Sparsentan tablets/Over-encapsulated Sparsentan tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-LT   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-EE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
      2018   Phase 3   EUCTR2017-004605-41-CZ   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Sparsentan tablets/Overencapsulated Sparsentan tablets
   Retrophin, Inc.
      2018   Phase 3   EUCTR2017-004605-41-GB   Australia;Belgium;Croatia;Czech Republic;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-DE   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Sparsentan tablets/over-encapsulated Spasenten tablets
   Travere Therapeutics Inc.
      2019   Phase 3   EUCTR2017-004605-41-PL   Australia;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Hong Kong;Italy;Korea, Republic of;Lithuania;New Zealand;Poland;Portugal;Spain;Taiwan;United Kingdom;United States;
Stasis
   Zhejiang Provincal Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2100042331   China;
Steroids plus azathioprine
   A. Manzoni Hospital
      1998   Phase 4   NCT00755859   Italy;Switzerland;
Supportive and immunosuppressive therapy
   RWTH Aachen University
      2008   Phase 3   NCT00554502   Germany;
Supportive therapy
   RWTH Aachen
      2008   -   EUCTR2007-000871-41-DE   Germany;
Supportive therapy with: ACE-inhibitor / ARB / Statin
   RWTH Aachen University
      2008   Phase 3   NCT00554502   Germany;
Tacrolimus
   Astellas Pharma Inc
      2010   Phase 2   NCT01224028   Korea, Republic of;
   Kidney Disease Center, The First Affiliated Hospital, College of Medicine, Zhejiang University
      2015   -   ChiCTR-IPR-15006760   China;
Tailored diet
   Uppsala University Hospital
      2010   -   NCT01203007   Norway;Sweden;
Telitacicept
   RemeGen Co., Ltd.
      2021   Phase 2   NCT04905212   United States;
Telmisartan
   Chinese General Hospital of PLA
      2010   -   ChiCTR-TRC-10000776   China;
   Xiyuan Hospital, China Academy of Chinese Medical Sciences
      2020   -   ChiCTR2000040161   China;
      2019   -   ChiCTR1900022100   China;
The Yi-Qi-Qing-Jie herbal compound
   Guang'anmen Hospital of China Academy of Chinese Medical Sciences
      2019   Phase 2/Phase 3   NCT03418779   China;
Tripterygium
   Hangzhou Hospital of Traditional Chinese Medicine
      2012   -   ChiCTR-TRC-12002228   China;
Tripterygium wilfordii (TW)
   Nanjing University School of Medicine
      2009   -   NCT00885547   China;
Ultomiris
   ALEXION PHARMACEUTICALS INCORPORATED
      2021   Phase 2   EUCTR2020-001537-13-IT   Australia;Belgium;Canada;France;Germany;Italy;Korea, Democratic People's Republic of;Netherlands;Poland;Singapore;Spain;Sweden;Taiwan;United Kingdom;United States;
VACCINO CONTRO IL MEMINGOCOCCO DI GRUPPO B
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
VACCINO PNEUMOCOCCICO
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
VACCINO POLISACCARIDICO ANTI-MENINGOCOCCICO (A.C.Y E W-135)
   NOVARTIS PHARMA AG
      2021   Phase 3   EUCTR2020-001049-38-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Democratic People's Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
VIS649
   Visterra, Inc.
      2020   Phase 2   EUCTR2019-002531-29-GB   Australia;Canada;Czech Republic;Hong Kong;India;Japan;Korea, Republic of;Malaysia;Philippines;Singapore;Spain;Taiwan;Thailand;United Kingdom;United States;
      2018   Phase 1   NCT03719443   United States;
VT-001
   Vera Therapeutics, Inc.
      2021   Phase 2   EUCTR2020-004892-41-GR   Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-004892-41-DE   Australia;Belarus;Belgium;Canada;Czech Republic;Czechia;Germany;Greece;India;Korea, Republic of;Malaysia;Poland;Turkey;United Kingdom;United States;
Valsartan
   ARB therapeutic society of IgA nephropathy
      2003   Phase 4   JPRN-C000000380   Japan;
   Columbia University
      2009   Phase 4   NCT01129557   United States;
   Guangdong General Hospital
      2007   Phase 4   NCT00426348   China;
   Peking Union Medical College Hospital
      2016   Phase 4   NCT02765594   China;
   Shuguang Hospital affliliated to Shanghai Univesrity of TCM
      2016   -   ChiCTR-IOR-16010174   China;
WM (Shentong Granules)
   Shanghai University of Traditional Chinese Medicine
      2016   -   NCT02712697   China;
Warfarin
   The Japanese Pediatric IgA Nephropathy of Treatment Study Group
      1998   -   JPRN-C000000375   Japan;
   The Japanese Pediatric IgA Nephropathy ofTreatment Study Group
      2001   -   JPRN-C000000363   Japan;
      1998   -   JPRN-C000000374   Japan;
LNP023 HYDROCHLORIDE SALT
   Novartis Pharma AG
      2022   Phase 3   EUCTR2020-002200-40-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-002200-40-NO   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-002200-40-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-002200-40-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2021   Phase 3   EUCTR2020-001049-38-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2021   Phase 3   EUCTR2020-001049-38-NO   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2021   Phase 3   EUCTR2020-001049-38-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2020   Phase 3   EUCTR2020-001049-38-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Vietnam;
      2020   Phase 3   EUCTR2020-001049-38-FI   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2020   Phase 3   EUCTR2020-001049-38-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;Norway;Russian Federation;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;Viet Nam;
      2019   Phase 2   EUCTR2017-000891-27-IT   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-000891-27-HU   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-000891-27-FR   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2019   Phase 2   EUCTR2017-000891-27-CZ   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-NL   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-FI   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-DK   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-DE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2018   Phase 2   EUCTR2017-000891-27-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
      2017   Phase 2   EUCTR2017-000891-27-GB   Argentina;Australia;Belgium;Brazil;Canada;China;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Hungary;India;Israel;Italy;Japan;Jordan;Korea, Republic of;Lebanon;Malaysia;Netherlands;Norway;Philippines;Singapore;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;